Amgen’s Aranesp, Procrit CIA Indications Okay For Incurable Cancers - ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel suggests new label saying the chemotherapy-induced anemia treatments are not indicated for patients with curable cancers, breast cancer or head and neck tumors.
You may also be interested in...
FDA Flexes New FDAAA Muscle With ESA Safety Labeling - And May Help Tone Up Amgen’s Franchise
Agency uses new authority to mandate label changes by Amgen and J&J in areas where negotiations were unsuccessful.
FDA Flexes New FDAAA Muscle With ESA Safety Labeling - And May Help Tone Up Amgen’s Franchise
Agency uses new authority to mandate label changes by Amgen and J&J in areas where negotiations were unsuccessful.
Amgen Seeks To Leave ESA Woes Behind In 2009
Aranesp sales are stabilizing, and Amgen expects to enter the new year with “steady-state” ESA sales, management says.